New Ways to Target Kidney Cancer

Strategies to Disrupt Oncogenic Transcription in RCC Tumors

NIH-funded research Georgetown University · NIH-11112428

This research looks for new and better ways to treat kidney cancer by targeting specific pathways that help tumors grow.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionGeorgetown University NIH-funded
Lab location1 site (Washington, United States)
Project IDNIH-11112428 on NIH RePORTER

What this research studies

We are exploring how certain proteins, called YAP/TAZ, act as master controllers for kidney cancer growth. Our team will test new medications designed to block these YAP/TAZ proteins in models derived from patient tumors. We will also use advanced techniques to understand how these new treatments change the cancer cells at a very detailed level. Ultimately, we aim to develop combination therapies that are more effective against kidney cancer.

Who could benefit from this research

Good fit: This foundational research focuses on understanding kidney cancer at a molecular level, and while it uses patient-derived models, it is not currently recruiting human participants.

Not a fit: Patients not diagnosed with renal cell carcinoma would not directly benefit from this specific research.

Why it matters

Potential benefit: If successful, this work could lead to new and more effective treatment options for patients with advanced kidney cancer.

How similar studies have performed: Preliminary studies suggest that targeting YAP/TAZ is a promising approach, and this work aims to develop first-in-class inhibitors.

Where this research is happening

Washington, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.